Gaurav Sikri1, Atul Kotwal2, S P Singh3, Srinivasa Bhattachar4, S S Bhatia5, Manohar Dutt6, N Srinath7. 1. Professor and Head, Department of Physiology, Armed Forces Medical College, Pune, 411040, India. 2. Dy DGAFMS (Pensions), O/o DGAFMS, Ministry of Defence, 'M' Block, New Delhi, 110001, India. 3. Professor, Department of Physiology, Armed Forces Medical College, Pune, 411040, India. 4. Assistant Professor, Department of Physiology, Armed Forces Medical College, Pune, 411040, India. 5. Commandant, Military Hospital Mhow, C/o 56 APO, India. 6. Commanding Officer, 4002 Field Hospital, C/o 56 APO, India. 7. Consultant (Surgery), O/o DGAFMS, Ministry of Defence, 'M' Block, New Delhi, 110001, India.
Abstract
BACKGROUND: In Western Himalayas, Indian Army soldiers take 11 days (6 days of acclimatization and 5 days of travel) on a sea-level to high altitude road (SH road) to reach a high altitude location (HAL) situated at an altitude of 11,500 feet from sea-level location (SLL) at an altitude of 1150 feet while following acclimatization schedule (AS). AS has an extra safety margin over the conventional 'mountaineering thumb rule' of not exceeding 500 m sleeping altitude above 3000 m altitude. We carried out this randomised field trial to study the feasibility of moving large number of troops rapidly from SLL to HAL on SH road in western Himalayas in 4 days under pharmaco-prophylaxis. METHODS: Based on the pharmaco-prophylaxis, at SLL 508 healthy lowland soldiers were divided into two groups: 'A' (n = 256) with Acetazolamide + Dexamethasone and 'B' (n = 252) with Acetazolamide + Placebo. They travelled rapidly by road to HAL in 4 days and prevalence of acute mountain sickness (AMS), high altitude pulmonary edema (HAPE) and high altitude cerebral edema (HACE) during the ascent was measured. RESULTS: Prevalence of AMS was found to be 1.56% and 1.59% in group 'A' and group 'B' respectively during the ascent with no cases of HAPE and HACE. CONCLUSION: At least on SH road, troops can be inducted rapidly to HAL from SLL in 4 days under pharmaco-prophylaxis with Acetazolamide with minimal occurrence of acute high altitude illnesses.
BACKGROUND: In Western Himalayas, Indian Army soldiers take 11 days (6 days of acclimatization and 5 days of travel) on a sea-level to high altitude road (SH road) to reach a high altitude location (HAL) situated at an altitude of 11,500 feet from sea-level location (SLL) at an altitude of 1150 feet while following acclimatization schedule (AS). AS has an extra safety margin over the conventional 'mountaineering thumb rule' of not exceeding 500 m sleeping altitude above 3000 m altitude. We carried out this randomised field trial to study the feasibility of moving large number of troops rapidly from SLL to HAL on SH road in western Himalayas in 4 days under pharmaco-prophylaxis. METHODS: Based on the pharmaco-prophylaxis, at SLL 508 healthy lowland soldiers were divided into two groups: 'A' (n = 256) with Acetazolamide + Dexamethasone and 'B' (n = 252) with Acetazolamide + Placebo. They travelled rapidly by road to HAL in 4 days and prevalence of acute mountain sickness (AMS), high altitude pulmonary edema (HAPE) and high altitude cerebral edema (HACE) during the ascent was measured. RESULTS: Prevalence of AMS was found to be 1.56% and 1.59% in group 'A' and group 'B' respectively during the ascent with no cases of HAPE and HACE. CONCLUSION: At least on SH road, troops can be inducted rapidly to HAL from SLL in 4 days under pharmaco-prophylaxis with Acetazolamide with minimal occurrence of acute high altitude illnesses.
Entities:
Keywords:
Acclimatization; Acetazolamide; Acute mountain sickness; Dexamethasone; High altitude
Authors: Andrew M Luks; Scott E McIntosh; Colin K Grissom; Paul S Auerbach; George W Rodway; Robert B Schoene; Ken Zafren; Peter H Hackett Journal: Wilderness Environ Med Date: 2010-03-10 Impact factor: 1.518
Authors: Marco Maggiorini; Hans-Peter Brunner-La Rocca; Simon Peth; Manuel Fischler; Thomas Böhm; Alain Bernheim; Stefanie Kiencke; Konrad E Bloch; Christoph Dehnert; Robert Naeije; Thomas Lehmann; Peter Bärtsch; Heimo Mairbäurl Journal: Ann Intern Med Date: 2006-10-03 Impact factor: 25.391
Authors: Manuel Fischler; Marco Maggiorini; Lorenz Dorschner; Johann Debrunner; Alain Bernheim; Stephanie Kiencke; Heimo Mairbäurl; Konrad E Bloch; Robert Naeije; Hans Peter Brunner-La Rocca Journal: Am J Respir Crit Care Med Date: 2009-06-11 Impact factor: 21.405